Business Wire

ITEN

21.11.2023 07:24:28 CET | Business Wire | Press release

Share
ITEN Named as CES 2024 Best of Innovation Awards Honoree

I-TEN,SA today announced that it has been named a CES® 2024 Best of Innovation Awards Honoree for its 250µA.h micro-battery This year’s CES Innovation Awards program received a record number of over 3000 submissions. The announcement was made ahead of CES 2024, the world’s most powerful technology event, happening Jan. 9-12 in Las Vegas, NV.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120706085/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Solid-state SMD Micro-battery (Photo: I-TEN SA)

The CES Innovation Awards program is an annual competition honoring outstanding design and engineering in 29 consumer technology product categories. Those with the highest rating receive the “Best of Innovation” distinction. An elite panel of industry expert judges, including members of the media, designers, engineers and more, reviewed submissions based on innovation, engineering and functionality, aesthetic and design.

ITEN are a French company manufacturing solid-state SMD micro-batteries. As a fully integrated device manufacturer, ITEN control the complete value chain from material synthesis up to the packaging and test. ITEN have raised more than 120M$ since the foundation of the company and their technology has been granted more than 300 patents worldwide so far.

The new 250µA.h micro-batteries have a footprint of #4,5 x 3,2 mm and have two more main features:
- they can be recharged quickly (80% in 8 minutes) and simply at constant voltage (like a capacitor);
- they can deliver high power and high peak currents, of more than 30mA over 100ms, meaning a C-Rate of more than 120.

The C-rate is a key performance for batteries used in low power IOT solutions. Such low-power IOT solutions do indeed consume less and less energy on the average but from time-to-time, the power supply must deliver current spikes to power RF transceivers, microcontrollers sensors or actuators for instance.

Thanks to the high C-rates of ITEN’s batteries, it is now possible to reduce the size and the capacity (by a factor up to 500 or 1000) of the batteries to be used in such IOT solutions: This also reduces the carbon footprint of the energy storage solutions by a factor at least 200 compared to coin cells and this even makes it possible to design ecofriendly autonomous solutions by combining energy harvesting solutions and a micro-battery of very small capacity. In addition, ITEN micro-batteries are ROHS and REACH compliant and contain neither toxic materials, nor heavy metals, nor solvents, no rare earths and do not require a specific recycling process at the end of the system life.

They are thus a concrete response to electronics designers looking for ecofriendly alternatives to coin cells. In this respect, ITEN solutions fit in with the European Directive recommending getting rid of non-rechargeable batteries in all electronic system designs from year 2030.

“We are thrilled and honored by this Best of Innovation Award at CES 2024. This recognizes our disruptive solid-state batteries as main contributors to sustainability, eco-design and smart energy solutions” stated Fabien Gaben, Chairman of the board and founder of the company. “This is really a breakthrough in the way of powering autonomous embedded systems.”

The CES 2024 Innovation Awards honorees, can be found at CES.tech/innovation. More will be revealed in January during CES Unveiled.

About ITEN:
ITEN is the leading company developing and manufacturing ecofriendly solid-state lithium-ion SMD micro batteries. Such micro batteries are rechargeable In a few minutes and can deliver power over a wide operating temperature range. They are used in many applications as back-up power supply, or to assist primary cells in delivering power or to power autonomous sensor nodes, tracking and monitoring solutions, sensor data loggers, beacons and RF tags, smartphone peripherals, medical devices, home and building automation, smart cities, wearables, and e-textiles.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231120706085/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye